AR111845A1 - Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos - Google Patents
Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismosInfo
- Publication number
- AR111845A1 AR111845A1 ARP180101001A ARP180101001A AR111845A1 AR 111845 A1 AR111845 A1 AR 111845A1 AR P180101001 A ARP180101001 A AR P180101001A AR P180101001 A ARP180101001 A AR P180101001A AR 111845 A1 AR111845 A1 AR 111845A1
- Authority
- AR
- Argentina
- Prior art keywords
- cgrp
- human
- antibodies
- useful
- autoimmune diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a anticuerpos biespecíficos de IgG que se unen al péptido relacionado con el gen de La calcitonina humana (CGRP) e interleucina-23 humana (IL-23) y se caracterizan por tener una alta afinidad y fuertes propiedades de neutralización simultánea tanto para CGRP humano como para IL-23 humana. Los anticuerpos biespecíficos son útiles para tratar diversas enfermedades autoinmunes, incluyendo la enfermedad inflamatoria intestinal, tales como la enfermedad de Crohn (CD) y colitis ulcerosa (UC), y otras enfermedades autoinmunes tales como artritis psoriásica (PSA), espondilitis anquilosante (AS) y dermatitis atópica (AtD). Los anticuerpos biespecíficos son útiles para tratar el dolor asociado con las enfermedades mencionadas anteriormente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762500754P | 2017-05-03 | 2017-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR111845A1 true AR111845A1 (es) | 2019-08-28 |
Family
ID=62148528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101001A AR111845A1 (es) | 2017-05-03 | 2018-04-19 | Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos |
Country Status (7)
Country | Link |
---|---|
US (1) | US10577415B2 (es) |
EP (1) | EP3618862A1 (es) |
JP (1) | JP6948457B2 (es) |
CN (1) | CN110573182B (es) |
AR (1) | AR111845A1 (es) |
TW (1) | TW201902926A (es) |
WO (1) | WO2018204156A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7090204B2 (ja) * | 2018-07-19 | 2022-06-23 | イーライ リリー アンド カンパニー | 免疫チェックポイントを標的とする二重特異性抗体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
JOP20140049B1 (ar) | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
-
2018
- 2018-04-19 AR ARP180101001A patent/AR111845A1/es unknown
- 2018-04-19 TW TW107113274A patent/TW201902926A/zh unknown
- 2018-04-26 CN CN201880028766.7A patent/CN110573182B/zh active Active
- 2018-04-26 US US15/963,167 patent/US10577415B2/en active Active
- 2018-04-26 WO PCT/US2018/029536 patent/WO2018204156A1/en unknown
- 2018-04-26 JP JP2020508971A patent/JP6948457B2/ja active Active
- 2018-04-26 EP EP18724084.1A patent/EP3618862A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018204156A1 (en) | 2018-11-08 |
CN110573182B (zh) | 2024-01-16 |
TW201902926A (zh) | 2019-01-16 |
CN110573182A (zh) | 2019-12-13 |
JP6948457B2 (ja) | 2021-10-13 |
EP3618862A1 (en) | 2020-03-11 |
US20180319880A1 (en) | 2018-11-08 |
US10577415B2 (en) | 2020-03-03 |
JP2020518280A (ja) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094877A1 (es) | Anticuerpos que se unen a il-23 | |
PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
PE20180046A1 (es) | Anticuerpos terapeuticos y sus usos | |
BR112019012570A8 (pt) | Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo | |
CL2017001090A1 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
UY33715A (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a) | |
HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
MX2016005765A (es) | Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos. | |
PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
ECSP099379A (es) | Anticuerpos anti-factor d humanizados | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
JP2017518258A5 (es) | ||
BR112017028550A2 (pt) | proteínas de fusão de fragmentos de proteína humana para criar composições de inmunoglobulina fc multimerizadas ordinárias com relação de complemento melhorado | |
AR103840A1 (es) | ANTICUERPOS IgG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS | |
AR094960A1 (es) | Anticuerpos de quimiocina pan-elr⁺ cxc | |
PE20170943A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
CO2023011962A2 (es) | Anticuerpos anti-cd30l y usos de estos | |
CL2022003755A1 (es) | Muteínas de il-10 y proteínas de fusión de las mismas | |
CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
PE20180797A1 (es) | Inmunoconjugados de il22 | |
BR112015018035A2 (pt) | anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno | |
AR111845A1 (es) | Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |